Has Amgen Already Won Its BPCIA Dispute With Sandoz?

Authors

Name

Brian D. Coggio

Person title

Of Counsel

By: Ron Vogel and Brian Coggio

Fish attorneys Brian Coggio and Ron Vogel recently published an article in Law360 where they discuss the Supreme Court determination “that Sandoz ‘violated’ the Biologics Price Competition and Innovation Act by failing to disclose its confidential information to Amgen. And according to the court, this violation is "unlawful" under California unfair competition law. Accordingly, has the disclosure issue been resolved?”

To read the full article, visit Law360.

The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.

Law360: Has Amgen Already Won Its BPCIA Dispute With Sandoz?

Authors

Should the Experimental Use Exception Be Broadened?

Duty of Disclosure and Consistency Requirements for Statements to PTO and Other Government Agencies

The Final Word on an Alleged Infringer’s Intent in a Hatch-Waxman Safe Harbor Analysis

Federal Circuit Reiterates That an Alleged Infringer’s Intent Is Irrelevant in a Hatch-Waxman Safe Harbor Analysis

Federal Circuit to Consider the Relevance of an Alleged Infringer’s “Intent” in a Hatch-Waxman Safe Harbor Analysis

Fish Attorneys Author IP Litigator Article, "Regenxbio v. Sarepta: Make Sure You're Safely Within the Safe Harbor Before Using a 'Research Tool'"

REGENXBIO v. SAREPTA: Make Sure You're Safely Within the Safe Harbor Before Using a "Research Tool"

Users of Research Tools Take Note

Attorneys for Branded Companies Should Carefully Review ANDAs for Admissions Regarding Generic Infringement

First Circuit Finds Device Patent Improperly Listed in the Orange Book

Cybersecurity Litigation Strategies: Jurisdiction

Introduction to SEP & FRAND Issues

Is Reverse Engineering Misappropriation of Trade Secrets?

How a Second Trump Presidency Could Shape IP

Texas Patent Litigation Monthly Wrap-Up: October 2024

Trade Secrets: A Powerful Alternative to Noncompete Agreements

Should the Experimental Use Exception Be Broadened?

Taking a Good Deposition, Part II: Asking the Right Kind of Questions and Asking Them in the Right Way

The Final Word on an Alleged Infringer’s Intent in a Hatch-Waxman Safe Harbor Analysis

Preparing Your Company for Hatch-Waxman